.svg)
END-to-END
AI Platform by GEn1E, for GEn1E
Our AI/ML Platform is Full-Chain and spans entire process from Discovery to Clinical Studies enabling efficient Drug Development. We have designed Machine Learning models that uses disease mapping databases to identify other indications for the drugs we have discovered, allowing us to broaden the scope of diseases which could be treated with our drugs. Neural Networks, Gradient Boosting Methods and Hidden Markov Models are being used to accelerate drug development.
Matching disease and drug signatures
Gene expression analyses show that GEn1E drugs are selective, immunomodulating and protect the anti-inflammatory pathways. This leads to safe and effective treatments for inflammatory diseases. Each inflammatory disease has its own unique signature as expressed with multiple biomarkers. GEn1E matches its drug’s unique signature with the inflammatory disease signature to select the best match of the drug for the disease.
GRID ™AI Platform
Generated Data
Lab
- Safety
- Toxicology
- PK/PD
Clinical Trial
- Our Phase 1 data
- NIH data sets
Disease & Gene
- Genomics
- Proteomics
Molecular Functional
- Mechanisms of action
- Disease pathways
Wet Lab Data
In vitro Experiments
Animal Experiments
Ex Vivo Experiments
Curated Data
Publications
Grey Literature
Partnership
Models & Training
- Monte Carlo Simulation
- Real-time Gradient Boosting
- Neural Networks
- Mix Model Management
- Scoring Stratification
- Personalization & Trajectory Mapping
Applications
- AI-powered endotyping for precision medicine
- Directed Drug-Disease Mapping
- RNA-Seq Gene Expression Profiling and Multi-omics Analysis
- Binding Pocket Characterization using Ligand Competitive Saturation
- Drug Screening Using SAR
- KG
Outputs
21
1st-in-class compounds
1
Asset in Phase 2
3
Preclinical programs
2.5
Years to Phase 2
Seed
Spend
© Copyright 2018-2024. All rights reserved.
%2C%20Color%3DOriginal.svg)
